Dermatologists gathered in Atlanta this month to debate how cross-trial efficacy data for three FDA-approved JAK inhibitors should shape treatment choices when patients bring hard deadlines, Dermatology Times reported of a case-based roundtable titled “Alopecia Areata in Practice: Individualizing Care Through Patient Cases.”
The event, moderated by Jessica Mercer, MD, a dermatologist, co-managing partner, and director of dermatopathology at Georgia Dermatology Partners, brought together dermatologists, nurse practitioners, and physician assistants to work through three cases and review deuruxolitinib (Leqselvi; Sun Pharmaceutical Industries), ritlecitinib (Litfulo; Pfizer), and baricitinib (Olumiant; Eli Lilly), Dermatology Times reported.
Why it matters: alopecia areata is an autoimmune condition in which the immune system attacks hair follicles, and the newest systemic therapies can regrow scalp hair — but only over months, and not in every patient. Matching drug to patient timeline has become a central clinical decision.
The first case set the stakes. A 33-year-old man had 45% scalp hair loss, minimal response to 4 months of topical corticosteroid, and a wedding in 6 months. In a poll, 47% of attendees named extent of scalp involvement as the top trigger for systemic escalation, and 41% named psychosocial or quality-of-life impact.
Cross-Trial Comparisons Are Unreliable
- Cross-trial comparisons of these drugs are unreliable: the trials used different endpoints, populations, and allowed add-on therapies.
- Speed of response matters — 69% of polled attendees called it extremely influential in drug selection.
- Severity is not just percentage of hair lost; eyebrows, eyelashes, and how fast loss is progressing count too.
The Numbers Behind the Debate
Mercer favors the Alopecia Areata Scale over the Severity of Alopecia Tool (SALT) alone, because secondary criteria such as eyebrow or eyelash involvement and rapid progression can move a patient into a higher severity category. SALT, in plain terms, scores hair loss as a percentage from 0 (no loss) to 100.
In pooled data from the THRIVE-AA1 and THRIVE-AA2 trials, 31.0% of patients on deuruxolitinib reached a SALT score of 20 or less at week 24, compared with 0.8% on placebo. In the BRAVE-AA1 trial, 22% of patients on baricitinib 2 mg and 38.8% on 4 mg reached the same threshold at week 36.
Mercer cautioned against comparing those numbers across trials, citing differences in end points, enrolled populations, and permitted adjunctive therapy — meaning some trials allowed additional treatments that could inflate results.
Exclusion Criteria Shape Real-World Results
“Looking at the exclusion criteria has been massive,” one attendee said, reflecting on how the fine print of who was enrolled shapes what real-world results look like. Some attendees reported mixed results with deuruxolitinib in adults, and others described baricitinib as slow. “It’s a slow burn,” an attendee said.
Payer requirements to start baricitinib at 2 mg drew criticism for patients with a defined timeline. “Why am I going to waste one of those months on a lower-dose medication?” an attendee said.
Attendees favored a cautiously optimistic message on timing, paired with a backup plan such as camouflage — wigs, fibers, or other cosmetic coverage while drug effects build. “Underpromise and overdeliver,” an attendee said.
Rapid Progression and Patient-Reported Outcomes
The second case featured a 29-year-old woman whose scalp hair loss rose from 21% to 36% in 3 months, with severe anxiety and no eyebrow or eyelash involvement. Attendees classified her as moderate by objective criteria, though one noted a possible ophiasis pattern — a band-like loss along the hairline that can behave differently.
All supported systemic therapy for her, a shift the poll numbers help explain: psychosocial impact alone, at 41% of attendees’ votes, sits just behind scalp extent as a trigger to escalate beyond topicals.
Access on Both Sides of the Atlantic
While the roundtable was US-based, the access question travels. All three drugs are approved by the FDA for severe alopecia areata; in Europe, the European Medicines Agency has approved baricitinib and ritlecitinib, and health technology assessment bodies such as the UK’s NICE weigh cost-effectiveness before NHS patients can receive them.
Step-therapy rules — like the 2 mg baricitinib start attendees criticized — are a payer mechanism, not a clinical one, and the roundtable discussion suggests they collide with time-sensitive patient goals.
| Trial | Drug and dose | SALT ≤20 achieved | Timepoint |
|---|---|---|---|
| THRIVE-AA1/AA2 (pooled) | Deuruxolitinib | 31.0% | Week 24 |
| THRIVE-AA1/AA2 (pooled) | Placebo | 0.8% | Week 24 |
| BRAVE-AA1 | Baricitinib 2 mg | 22% | Week 36 |
| BRAVE-AA1 | Baricitinib 4 mg | 38.8% | Week 36 |
What the table cannot show is whether deuruxolitinib outperforms baricitinib — the trials were run separately, with different rules, and Mercer warned against reading the percentages head to head.
Contraindications & When to Consult a Doctor
JAK inhibitors work by blocking Janus kinase pathways involved in immune signaling, which means they carry infection, blood-count, and lipid risks that require monitoring.
Anyone with active or latent infection, a history of blood clots, or major cardiovascular risk factors should discuss these with a dermatologist before starting, and treatment decisions belong with a physician who can review each drug's prescribing information and monitoring requirements. Rapidly progressive hair loss, new eyebrow or eyelash involvement, or severe psychological distress warrant prompt evaluation rather than waiting for a scheduled follow-up.
Where the Roundtable Leaves the Field
The meeting closed on the tension the first case posed: pooled trial percentages are the best available evidence, but they were never designed to answer the question a bride, a groom, or a patient with a rapidly progressing ophiasis pattern actually asks. “Looking at the exclusion criteria has been massive,” the attendee said.
References
- Dermatology Times — Case-Based Roundtable: “Alopecia Areata in Practice: Individualizing Care Through Patient Cases,” moderated by Jessica Mercer, MD, Atlanta, Georgia.
- Pooled efficacy data from the THRIVE-AA1 and THRIVE-AA2 phase 3 trials of deuruxolitinib.
- Efficacy data from the BRAVE-AA1 phase 3 trial of baricitinib.
- US Food and Drug Administration approvals of deuruxolitinib, ritlecitinib, and baricitinib for severe alopecia areata.